The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
Abstract
PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of bone metastases in breast cancer and their role relative to other therapies for this condition. METHODS: An expert multidisciplinary panel reviewed pertinent information from the published literature and meeting abstracts through May 1999. Additional data collected as part of randomized trials and submitted to the United States Food and Drug Administration were also reviewed, and investigators were contacted for more recent information. Values for levels of evidence and grade of recommendation were assigned by expert reviewers and approved by the panel. Expert consensus was used if there were insufficient published data. The panel addressed which patients to treat and when in their course of disease, specific drug delivery issues, duration of therapy, management of bony metastases with other therapies, and the public policy implications. The guideline underwent external review by selected physicians, members of the American Society of Clinical Oncology (ASCO) Health Services Research Committee, and the ASCO Board of Directors. RESULTS: Bisphosphonates have not had an impact on the most reliable cancer end point: overall survival. The benefits have been reductions in skeletal complications, ie, pathologic fractures, surgery for fracture or impending fracture, radiation, spinal cord compression, and hypercalcemia. Intravenous (IV) pamidronate 90 mg delivered over 1 to 2 hours every 3 to 4 weeks is recommended in patients with metastatic breast cancer who have imaging evidence of lytic destruction of bone and who are concurrently receiving systemic therapy with hormonal therapy or chemotherapy. For women with only an abnormal bone scan but without bony destruction by imaging studies or localized pain, there is insufficient evidence to suggest starting bisphosphonates. Starting bisphosphonates in patients without evidence of bony metastasis, even in the presence of other extraskeletal metastases, is not recommended. Studies of bisphosphonates in the adjuvant setting have yielded inconsistent results. Starting bisphosphonates in patients at any stage of their nonosseous disease, outside of clinical trials, despite a high risk for future bone metastasis, is currently not recommended. Oral bisphosphonates are one of several options which can be used for preservation of bone density in premenopausal patients with treatment-induced menopause. The panel suggests that, once initiated, IV bisphosphonates be continued until evidence of substantial decline in a patient’s general performance status. The panel stresses that clinical judgment must guide what is a substantial decline. There is no evidence addressing the consequences of stopping bisphosphonates after one or more adverse skeletal events. Symptoms in the spine, pelvis, or femur require careful evaluation for spinal cord compression and pathologic fracture before bisphosphonate use and if symptoms recur, persist, or worsen during therapy. The panel recommends that current standards of care for cancer pain, analgesics and local radiation therapy, not be displaced by bisphosphonates. IV pamidronate is recommended in women with pain caused by osteolytic metastasis to relieve pain when used concurrently with systemic chemotherapy and/or hormonal therapy, since it was associated with a modest pain control benefit in controlled trials. CONCLUSION: Bisphosphonates provide a meaningful supportive but not life-prolonging benefit to many patients with bone metastases from cancer. Further research is warranted to identify clinical predictors of when to start and stop therapy, to integrate their use with other treatments for bone metastases, to identify their role in the adjuvant setting in preventing bone metastases, and to better determine their cost-benefit consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Landis, S. H., Murray, T., Bolden, S., & Wingo, P. A. (1998) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.48.1.6 · Cited by 2,341
Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents
Sackett, D. L. (1989) · Chest · doi:10.1378/chest.95.2_supplement.2s · Cited by 1,368
Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Self-citationBisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Self-citationHortobagyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J. J., Knight, R. D., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 631
Self-citationTreatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Cited by
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
Coleman, R. E. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0210 · Cited by 1,920
Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W., Smith, T. J., Baker Jr, S., Olak, J., Stover, D., Strawn, J. R., Turrisi, A. T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,413
Self-citationOsteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors
Bamias, A., Kastritis, E., Bamia, C., Moulopoulos, L. A., Melakopoulos, I., Bozas, G., Koutsoukou, V., Gika, D., Anagnostopoulos, A., Papadimitriou, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8670 · Cited by 1,149
Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report
Cherny, N., Ripamonti, C., Pereira, J., Davis, C., Fallon, M., McQuay, H., Mercadante, S., Pasternak, G., Ventafridda, V., & for the Expert Working Group of the European Association of Palliative Care Network (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2542 · Cited by 626
Brown, J. E., Cook, R. J., Major, P., Lipton, A., Saad, F., Smith, M., Lee, K.-A., Zheng, M., Hei, Y.-J., & Coleman, R. E. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji002 · Cited by 559
Self-citationKohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.116 · Cited by 546
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Self-citationA systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Body, J.-J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., & Bergström, B. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg367 · Cited by 413
Ripamonti, C. I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., Bareggi, C., Ascani, L., & Cislaghi, E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn526 · Cited by 405
Hansen, T., Kunkel, M., Weber, A., & James Kirkpatrick, C. (2006) · Journal of Oral Pathology & Medicine · doi:10.1111/j.1600-0714.2006.00391.x · Cited by 368
Ruggiero, S. L., Gralow, J. R., Marx, R. E., Hoff, A. O., Schubert, M. M., Huryn, J. M., Toth, B., Damato, K., & Valero, V. (2006) · Journal of Oncology Practice · doi:10.1200/jop.2.1.7 · Cited by 355
Van Poznak, C. H., Temin, S., Yee, G. C., Janjan, N. A., Barlow, W. E., Biermann, J. S., Bosserman, L. D., Geoghegan, C., Hillner, B. E., Theriault, R. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5209 · Cited by 342
Self-citationSmall, E. J., Smith, M. R., Seaman, J. J., Petrone, S., & Kowalski, M. O. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.147 · Cited by 341
Body, J. J., Diel, I. J., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., Tripathy, D., & Bergstrom, B. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601663 · Cited by 336
Rosen, L. S., Gordon, D. H., Dugan, W., Major, P., Eisenberg, P. D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B., et al. (2004) · Cancer · doi:10.1002/cncr.11892 · Cited by 335
Tumour macrophages as potential targets of bisphosphonates
Rogers, T. L., & Holen, I. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-177 · Cited by 324
Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., Holen, I., Mönkkönen, H., Boccadoro, M., Forni, G., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00926.x · Cited by 275
Management of bone metastases in cancer: A review
Selvaggi, G., & Scagliotti, G. V. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.011 · Cited by 266
Price, J. T., Quinn, J. M. W., Sims, N. A., Vieusseux, J., Waldeck, K., Docherty, S. E., Myers, D., Nakamura, A., Waltham, M. C., Gillespie, M. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4458 · Cited by 142
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Metadata
- Authors
- Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., Yee, G., Biermann, J. S., Chlebowski, R. T., Pfister, D. G., & for the American Society of Clinical Oncology Bisphosphonates Expert Panel
- Venue
- Journal of Clinical Oncology
- Published
- 2000-03-13
- Volume
- 18
- Issue
- 6
- Pages
- 1378-1391
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122560580
- Cited by
- 383
- References
- 45
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.